Unicycive Therapeutics, Inc. (UNCY) Stock Forecast
UNCY analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 10 analysts
- Price target
- $28.40 average of analyst targets
- Upside to target
- +745.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.33
- 52-week range
- $3.36 – $8.56
UNCY analyst ratings
10 analystsNumber of analysts at each rating.
UNCY price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
UNCY earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.66 | −$0.23 | −$0.33 | −6.4% | 9 |
| Current fiscal year (2026) | −$1.27 | −$1.61 | −$0.62 | −$1.67 | +24.2% | 9 |
| Next fiscal year (2027) | $1.69 | −$0.96 | $5.53 | −$1.27 | +233.2% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
UNCY revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $1.4M | $0 | $10.4M | 0.0% | 10 |
| Next fiscal year (2027) | $149.5M | $27.5M | $307.2M | +10,812.6% | 9 |
UNCY EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
UNCY revenue: reported and forecast
UNCY EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.36 | −$0.36 | −$0.35 | −$0.35 | −$0.35 | −3.5% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.50 | −$1.50 | −$1.23 | −$1.23 | −$1.27 | −15.5% | 1 up · 0 down |
| Next fiscal year (2027) | $5.10 | $5.10 | $1.66 | $1.66 | $1.69 | −67.0% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
UNCY earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; UNCY beat in 8 of 12.
What analysts expect from UNCY
10 analysts cover Unicycive Therapeutics; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $28.40, 745.2% above the latest close of $3.36. Analysts expect earnings of −$1.27 per share for 2026, +24.2% from a year earlier. For 2027 the average estimate is $1.69 per share on revenue of $149.5 million. Unicycive Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: UNCY income statement, UNCY key metrics, UNCY chart. See the UNCY stock overview for the latest quote and news.
UNCY forecast FAQ
What is Unicycive Therapeutics's price target?
The average analyst price target for Unicycive Therapeutics is $28.40, 745.2% above the latest close of $3.36.
Is Unicycive Therapeutics a buy, hold or sell?
Of 10 analysts covering Unicycive Therapeutics, 8 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Unicycive Therapeutics's EPS forecast?
Analysts forecast −$1.27 per share for 2026 (range −$1.61 to −$0.62); for 2027 the estimate is $1.69.
What is Unicycive Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $1.4 million, growth of 0.0%; for 2027 it is $149.5 million.
When does Unicycive Therapeutics report earnings?
Unicycive Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.33.
Does Unicycive Therapeutics usually beat earnings estimates?
Unicycive Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.